SAN FRANCISCO, Nov. 23, 2017 (GLOBE NEWSWIRE) -- André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.

Included in this article is: ProMIS Neurosciences Inc. (TSX:PMN)

In a Nov. 13, 2017 research note, analyst André Uddin with Mackie Research Capital Corp. reported that, as expected, ProMIS Neurosciences Inc. announced $0 revenue for Q3/17. Fully diluted earnings per share was ($0.01), which was in line with Mackie's estimate. At the quarter's end, the biotech had CA$3.3 million in cash and no debt. "Financials are less important as ProMIS is still a preclinical biotech company," wrote Uddin regarding the Q3/17 results.

ProMIS, Uddin continued, is developing PMN310 as a "novel Alzheimer's drug candidate based on a new amyloid beta theory—the disease is mainly caused by soluble toxic amyloid beta oligomers."

Mackie expects at least two upcoming catalysts for ProMIS. One is that the firm expects ProMIS "to disclose more preclinical results that should demonstrate a better efficacy and safety profile of PMN310 than Biogen's aducanumab," Uddin stated.

Continue reading this article: 'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate 

About Streetwise Reports – The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports. 

Please see the end of the article for the complete disclosures: 'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate